BC Innovations | Aug 23, 2019
Distillery Therapeutics

KRAS inhibitor combinations for improved therapeutic efficacy

DISEASE CATEGORY: Cancer INDICATION: Lung cancer, pancreatic cancer UCSF’s Kevan Shokat and colleagues have identified two sets of genes for which inhibition could improve the efficacy of KRAS G12C inhibitors. Through a CRISPR-based screen in...
BC Innovations | Sep 15, 2016
Distillery Therapeutics

Therapeutics: Angiogenin ribonuclease RNase A family 5 (ANG)

Hematology INDICATION: Bone marrow transplant (BMT); poisoning Cell culture and mouse studies suggest ANG could help improve outcomes in BMT patients and treat radiation damage. In cultures of primary mouse hematopoietic stem cells (HSCs), recombinant...
BioCentury | Aug 15, 2016
Emerging Company Profile

Restraining translation

Bantam Pharmaceutical LLC is developing small molecule eukaryotic translation initiation factor 4E inhibitors that selectively inhibit translation of several tumor-promoting genes and disrupt cancer cell metabolism. It hopes to show the mechanism of its lead...
BioCentury | Jun 13, 2016
Product Development

Basket cases

Both the Genentech Inc. unit of Roche and Novartis AG are using basket trials to study targeted cancer agents more efficiently. Genentech's initial forays could yield rare subpopulation data to bring its marketed therapies into...
BioCentury | Dec 14, 2015
Product Development

Following CoMMpass

Amidst a flood of promising data for hot targets, indications and technologies at this year's American Society of Hematology meeting, one collection of presentations stands out not only for the wide-reaching implications of their data,...
BC Innovations | Sep 24, 2015
Distillery Techniques

Techniques: SNPs on oligonucleotide/oligosaccharide-binding fold containing 1 (OBFC1) and other loci as risk markers of cutaneous malignant melanoma

Biomarkers OBFC1 cyclin D1 CCND1 BCL1 oligonucleotide/oligosaccharide-binding fold containing 1 (OBFC1) QIMR Berghofer Medical Research Institute University of Leeds...
BC Innovations | Jun 18, 2015
Distillery Techniques

Techniques: Crystal structure of myeloid leukemia cell differentiation protein (MCL1)

Drug platforms TECHNOLOGY: Crystal structures Crystallographic studies on an MCL1 fusion protein could aid the structure-based design of MCL1-specific inhibitors. A fusion of maltose binding protein and MCL1 containing three mutations to enhance its crystal...
BC Innovations | Apr 30, 2015
Distillery Therapeutics

Therapeutics: Myeloid leukemia cell differentiation protein (MCL1); B cell lymphoma 2 (BCL-2; BCL2); Bcl-XL

Cancer INDICATION: Cancer In vitro studies identified a tricyclic indole-based, selective inhibitor of MCL1 that could help treat cancer. Fragment-based drug design, chemical synthesis and in vitro testing of tricyclic 2-indole carboxylic acid analogs identified...
BC Innovations | Aug 29, 2013
Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Breast cancer; prostate cancer Androgen receptor; cyclin D1 (CCND1; BCL1) In vitro and mouse studies identified acetamide analog small molecules that...
BC Week In Review | Dec 10, 2012
Clinical News

PD-0332991: Additional Phase II data

Combined data from 66 postmenopausal women with estrogen receptor-positive, HER2-negative advanced breast cancer in part 1 and 99 postmenopausal women whose tumors revealed cyclin D1 ( CCND1 ; BCL1 ) amplification and p16 loss in part 2...
Items per page:
1 - 10 of 48